

Journal of Clinical Research in Diabetes and Medicine

J Clin Res Diabetes Med 2020

Pembrolizumab induced hypophysitis in a patient allergic to Triamcinolone: An increasingly recognized endocrinopathy related to immunotherapy

Rezaul Haider Chowdhury

Changi General Hospital, Singapore

Abstract:

We would like to describe the clinical course of a 61-year-old gentleman known to have Stage IV left lower lobe lung adenocarcinoma who presented to us with unintentional loss of weight for four months, easy fatigability and breast pain while showering. He was started on pembrolizumab immunotherapy about 9 months before presentation which he tolerated well. Subsequent endocrine work ups revealed features consistent with hypophysitis that lead to hypopituitarism in the form of secondary adrenal insufficiency and hypothyroidism. While more and more patients are receiving novel anti-cancer treatment for example immunotherapy, we should never forget and address the side effects it brings along. This study certainly supports above mentioned suggestion.

Article Information

Conferenc Proceedings: Online Congress on Diabetes &

Endocrinology

Conferecne date: September 23-24, 2020

Inovineconferences.com

*Corresponding author: Changi General Hospital,

Singapore Email: reza20134@ymail.com

Citation: Chowdhury RH (2020) Pembrolizumab induced hypophysitis in a patient allergic to Triamcinolone: An increasingly recognized endocrinopathy related to immunotherapy. J Clin Res Diabetes Med

Copyright: © 2020 Chowdhury RH. This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.